Tag - MTNB

Executive Moves

Matinas names Keith Murphy and Edward Neugeboren to BOD

Matinas BioPharma (NYSE American:MTNB) has appointed biotech industry veterans Keith Murphy and Edward Neugeboren to its board of directors (BOD) as independent members, effective today. Also effective today, Matinas...

March 11, 2025

Developments

Matinas gets FDA fast track, QIDP designations for MAT2203

The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal...

July 25, 2019

Markets

HCW starts 2 omega-3 companies at buy

H.C. Wainwright launched coverage of Acasti Pharma (NASDAQ:ACST) and Matinas BioPharma (NYSE American:MTNB) with “buy” ratings and price targets of $6 and $4, respectively.

June 26, 2019

Markets

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...

April 23, 2018

Tag - MTNB

Matinas names Keith Murphy and Edward Neugeboren to BOD

Matinas gets FDA fast track, QIDP designations for MAT2203

HCW starts 2 omega-3 companies at buy

Maxim cuts Matinas BioPharma PT to $4 from $6

Subscribe